Darapladib after ACS did not lower risk for subsequent events

August 31, 2014 5:16 PM

12 0

After ACS, direct inhibition of lipoprotein-associated phospholipase A2 with darapladib did not prove successful in reducing the risk for coronary events when compared with placebo.

A total of 13,026 patients (mean age, 64 years; 74.5% men) were included in the study within 30 days of hospitalization with an ACS who were randomly assigned once-daily darapladib 160 mg (n=6,504) or matching placebo (n=6,522) along with guideline-recommended therapy.

Read more

To category page